The global demand for Benign Prostatic Hyperplasia Treatment Market is presumed to reach the market size of nearly USD 10.75 MN by 2028 from USD 8.12 MN in 2021 with a CAGR of 7.62% under the study period 2022 - 2028.
BPH stands for benign prostatic hyperplasia, which is a noncancerous cell proliferation inside the prostate gland. The inside of the prostate is first affected. The urethra then gradually becomes compressed as a result of prostatic enlargement. BPH medicines, surgery, and minimally invasive surgery are among viable medical treatments for BPH. These procedures aid in reducing the aberrant prostrate growth or relaxing the smooth bladder muscles.
The main drivers of advancement are the high incidence of BPH, rising preference for minimally invasive procedures, and rising grants, investments, and funding for the development of innovative treatments. Furthermore, the incidence of BPH is greatly influenced by the ageing population, especially the senior male segment, which drives the demand for pharmaceuticals worldwide. The market for benign prostatic hyperplasia prostate treatment is also anticipated to benefit from the rise in obesity, physical inactivity, and increased awareness of the existence of drugs for treating benign prostatic hyperplasia.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of benign prostatic hyperplasia treatment. The growth and trends of benign prostatic hyperplasia treatment industry provide a holistic approach to this study.
This section of the benign prostatic hyperplasia treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
- Drug Class (Alpha-Blockers, 5-Alpha-Reductase Inhibitor (5-ARIs), Phosphodiesterase-5 Enzyme Inhibitor, Others)
- Minimally Invasive Surgeries (Transurethral Resection Of The Prostate (TURP), Transurethral Incision Of The Prostate (TUIP), Robotic Surgeries, Transurethral Microwave Thermotherapy (TUMT), Prostatic Urethral Lift, Others)
- Laser Therapy
- Ambulatory Surgical Centers
- Specialty Clinics
This section covers the regional outlook, which accentuates current and future demand for the Benign Prostatic Hyperplasia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Benign Prostatic Hyperplasia Treatment Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the benign prostatic hyperplasia treatment market include Boston Scientific Corporation, Teleflex Incorporated, Endo International Plc, Urologix LLC, LISA Laser, Olympus Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.